Latest News-四川科伦博泰生物医药股份有限公司 Mediaroom_Page

Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting

CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6...

2025-04-24 13:17 2198

Kelun-Biotech's novel ADC drug SKB518 has been granted the clearance of IND from the United States Food and Drug Administration (FDA)

CHENGDU, China, April 21, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (t...

2025-04-21 20:10 3760

Clinical research results for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, a top international medical journal

CHENGDU, China, April 12, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (t...

2025-04-12 17:20 4250

ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024

Notable Progress in R&D and Commercialization Gross Profit Surging 68% FINANCIAL HIGHLIGHTS • Re...

2025-03-26 19:08 3021

Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

CHENGDU, China, March 26, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (t...

2025-03-26 10:45 1885

Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) Approved for Marketing in Second Indication by NMPA for EGFRm NSCLC

CHENGDU, China, March 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (t...

2025-03-10 19:22 1852

Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium

CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) G...

2025-02-13 11:25 2001

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC

CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-01-23 13:44 3451

Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).

CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2025-01-11 17:07 5030

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC

CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (th...

2024-11-27 14:34 2643

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") ba...

2024-10-31 12:34 2208

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") ba...

2024-10-31 12:02 2146

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical...

2024-09-29 11:52 3237

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

Three Study Results Abstracts From Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today

CHENGDU, China, Sept. 9, 2024 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Cong...

2024-09-09 14:27 1985

Three Study Results Abstracts From Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) At 2024 ESMO Released Today

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Aug. 20, 2024 /PRNewswire/ -- On August 20, the new drug application (NDA) for the ...

2024-08-20 16:32 2386

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLC

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference（"JPM...

2024-01-11 17:55 2307

CEO of Kelun-Biotech Dr. Micheal Ge delivered a presentation on The 42nd JPM Annual Healthcare Conference

SAN FRANCISCO, Jan. 11, 2024 /PRNewswire/ -- The 42nd J.P. Morgan Annual Healthcare Conference（"JPM...

2024-01-11 16:32 2684

Prof. Yongmei Yin at 2023 ESMO: SKB264 (MK-2870), an innovativeTROP2-ADC originating from Chinese biotech, achieves remarkable success in overcoming the therapeutic impasse in HR+/HER2- metastatic breast cancer

CHENGDU, China, Oct. 26, 2023 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) conv...

2023-10-26 12:58 2542

Based on recent data presented at 2023 ESMO, the innovative TROP2 ADC SKB264 (MK-2870) shows promising prospects for the treatment of patients with HR+/HER2- metastatic breast cancer who have undergone multiple prior lines of therapy , and its clinical development in other solid tumors is also advancing steadily

CHENGDU, China, Oct. 24, 2023 /PRNewswire/ -- Human trophoblastic cell surface antigen 2 (TROP2) ex...

2023-10-24 10:19 3110

The team from Kelun-Biotech held a meeting with representatives from MSD in Madrid, Spain

CHENGDU, China, Oct. 23, 2023 /PRNewswire/ -- On October 20, 2023, the European Society for Medical...

2023-10-23 18:16 2573